Bristol-Myers Squibb Co (BMY) to pay $0.41 on May 1, 2019; Employers Holdings (EIG) Shorts Increased By 2.17%

Bristol-Myers Squibb Company (NYSE:BMY) Logo

Bristol-Myers Squibb Co (NYSE:BMY) is expected to pay $0.41 on May 1, 2019. (NYSE:BMY) shareholders before Apr 4, 2019 will receive the $0.41 dividend. Bristol-Myers Squibb Co’s current price of $49.89 translates into 0.82% yield. Bristol-Myers Squibb Co’s dividend has Apr 5, 2019 as record date. Mar 7, 2019 is the announcement. The stock decreased 2.12% or $1.08 during the last trading session, reaching $49.89. About 30.84 million shares traded or 65.94% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has declined 19.24% since March 15, 2018 and is downtrending. It has underperformed by 23.61% the S&P500. Some Historical BMY News: 22/03/2018 – Rhode Island DoA: Bristol Rogers Free Library Thu, 3/22/2018, 7:30 PM; 29/05/2018 – Roche’s Tecentriq meets targets in lung cancer trial; 16/04/2018 – PFS RATE AFTER 1 YEAR 43 PCT FOR BRISTOL-MYERS’ OPDIVO PLUS YERVOY VS 13 PCT FOR CHEMOTHERAPY – DATA; 28/03/2018 – IPSEN ANNOUNCES EMA VALIDATION OF FILING OF A NEW APPLICATION FOR ADDITIONAL INDICATION FOR CABOMETYX®, FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC); 28/03/2018 – Exelixis’ Partner lpsen Announces EMA Validation of the Application for a New lndication for CABOMETYX® (cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma; 20/03/2018 – Roche: Tecentriq, Chemotherapy to Treat a Type of Advanced Lung Cancer; 16/04/2018 – Bristol-Myers invites J&J into an alliance of giants on cardio drug development/commercialization program $BMY $JNJ; 25/05/2018 – AstraZeneca cancer drug hits second goal by extending survival; 16/04/2018 – BRISTOL-MYERS SQUIBB CO – THERE WERE NO STATISTICALLY SIGNIFICANT DIFFERENCES BETWEEN 2 ARMS FOR PFS FOR OPDIVO & INVESTIGATOR’S CHOICE, RESPECTIVELY; 27/04/2018 – BRISTOL-MYERS SQUIBB CO BMY.N : BMO RAISES TO MARKET PERFORM FROM UNDERPERFORM

Employers Holdings Inc (NYSE:EIG) had an increase of 2.17% in short interest. EIG’s SI was 872,100 shares in March as released by FINRA. Its up 2.17% from 853,600 shares previously. With 139,400 avg volume, 6 days are for Employers Holdings Inc (NYSE:EIG)’s short sellers to cover EIG’s short positions. The SI to Employers Holdings Inc’s float is 2.74%. The stock increased 1.02% or $0.42 during the last trading session, reaching $41.48. About 202,206 shares traded or 17.62% up from the average. Employers Holdings, Inc. (NYSE:EIG) has risen 6.13% since March 15, 2018 and is uptrending. It has outperformed by 1.76% the S&P500. Some Historical EIG News: 25/04/2018 – EMPLOYERS HOLDINGS INC QTRLY GROSS PREMIUMS WRITTEN OF $211.6 MLN, UP 7% YEAR-OVER-YEAR; 23/04/2018 – DJ Employers Holdings Inc, Inst Holders, 1Q 2018 (EIG); 25/04/2018 – Employers Holdings 1Q Adj EPS 88c Vs. -; 25/04/2018 – Employers Holdings 1st-Quarter Net Premiums Earned $176.6 Million; 15/03/2018 EMPLOYERS HOLDINGS IN LETTER OF CREDIT PACTS W/ FHLB SF; 25/04/2018 – Employers Holdings 1Q EPS 77c; 25/04/2018 – Employers Holdings 1st-Quarter Gross Premiums Written $211.6 Million; 25/04/2018 – EMPLOYERS HOLDINGS 1Q OPER EPS 88C, EST. 53C; 25/04/2018 – Employers Holdings 1Q Adj EPS 88c; 25/04/2018 – EMPLOYERS HOLDINGS INC QTRLY NET EARNED PREMIUMS WERE $176.6 MILLION, AN INCREASE OF 1% YEAR-OVER-YEAR – SEC FILING

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $81.45 billion. The firm offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus infection. It has a 16.57 P/E ratio. The Company’s products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Among 9 analysts covering Bristol-Myers Squibb (NYSE:BMY), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Bristol-Myers Squibb had 14 analyst reports since October 8, 2018 according to SRatingsIntel. As per Thursday, February 28, the company rating was maintained by BMO Capital Markets. The firm has “Hold” rating by Guggenheim given on Tuesday, November 27. On Monday, October 22 the stock rating was downgraded by Citigroup to “Neutral”. The stock has “Overweight” rating by JP Morgan on Monday, October 8. The company was maintained on Tuesday, October 23 by BMO Capital Markets. The firm earned “Neutral” rating on Tuesday, February 19 by Bank of America. The rating was upgraded by BMO Capital Markets to “Outperform” on Thursday, December 6. BMO Capital Markets maintained Bristol-Myers Squibb Company (NYSE:BMY) on Friday, November 16 with “Market Perform” rating. Morgan Stanley maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Tuesday, November 6. Morgan Stanley has “Equal-Weight” rating and $59 target. On Friday, October 12 the stock rating was maintained by Barclays Capital with “Equal-Weight”.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Seekingalpha.com which released: “Starboard gauges support for BMY-CELG deal – Seeking Alpha” on February 17, 2019, also Seekingalpha.com with their article: “Celgene merger on track – BMY – Seeking Alpha” published on February 20, 2019, Streetinsider.com published: “Bristol-Myers Squibb (BMY)/Celgene (CELG) Merger Spread Continues to Narrow – StreetInsider.com” on March 14, 2019. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Seekingalpha.com and their article: “Bristol-Myers “disappointed” with Wellington position on Celgene deal – Seeking Alpha” published on February 28, 2019 as well as Seekingalpha.com‘s news article titled: “Barclays remains bullish on Bristol-Myers – Celgene tie-up – Seeking Alpha” with publication date: March 07, 2019.

Investors sentiment decreased to 0.78 in Q4 2018. Its down 0.10, from 0.88 in 2018Q3. It dived, as 89 investors sold Bristol-Myers Squibb Company shares while 550 reduced holdings. 126 funds opened positions while 371 raised stakes. 1.16 billion shares or 2.02% more from 1.14 billion shares in 2018Q3 were reported. Ashford Capital Mngmt Incorporated has invested 0.06% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Lynch & Associate In holds 0.26% in Bristol-Myers Squibb Company (NYSE:BMY) or 13,503 shares. Artisan Ptnrs Partnership owns 621,619 shares. Great Lakes Advisors Ltd Limited Liability Company accumulated 74,311 shares. Grace White Inc invested 0.13% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Highlander Mngmt Lc accumulated 25,124 shares or 0.86% of the stock. Colonial Tru Advisors owns 5,073 shares. Tekla Mngmt Ltd has 652,966 shares. Diversified Trust Com stated it has 0.04% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Mogy Joel R Investment Counsel Inc has 0.25% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 31,095 shares. The New York-based Meyer Handelman has invested 1.88% in Bristol-Myers Squibb Company (NYSE:BMY). Bonness Enterprises holds 2.07% or 53,100 shares. Bogle Invest Mgmt L P De holds 1.01% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 249,815 shares. John G Ullman Associates Inc invested in 236,799 shares or 2.48% of the stock. Bb&T has 0.35% invested in Bristol-Myers Squibb Company (NYSE:BMY).

More notable recent Employers Holdings, Inc. (NYSE:EIG) news were published by: Seekingalpha.com which released: “Employers Holdings declares $0.22 dividend – Seeking Alpha” on February 20, 2019, also Seekingalpha.com with their article: “Employers Holdings, Inc. (EIG) CEO Doug Dirks on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” published on February 21, 2019, Seekingalpha.com published: “EIG says will bid for Petrobras’ TAG pipeline amid three-week deadline – Seeking Alpha” on March 14, 2019. More interesting news about Employers Holdings, Inc. (NYSE:EIG) were released by: Globenewswire.com and their article: “Consolidated Research: 2019 Summary Expectations for Activision Blizzard, Marvell Technology Group, The Sherwin-Williams, T. Rowe Price Group, Employers, and Blue Bird — Fundamental Analysis, Key Performance Indications – GlobeNewswire” published on February 27, 2019 as well as Businesswire.com‘s news article titled: “Employers Holdings, Inc. Reports Fourth Quarter 2018 Results – Business Wire” with publication date: February 20, 2019.

Employers Holdings, Inc., through its subsidiaries, operates in the commercial property and casualty insurance industry primarily in the United States. The company has market cap of $1.36 billion. It offers workers' compensation insurance to small businesses in low to medium hazard industries. It has a 9.78 P/E ratio. The firm markets its products through independent local, regional, and national agents and brokers; and alternative distribution channels comprising its partners, as well as through national, regional, and local trade groups and associations.

Since September 17, 2018, it had 0 insider buys, and 3 insider sales for $442,350 activity. $129,000 worth of Employers Holdings, Inc. (NYSE:EIG) was sold by Ormsby Lenard T on Monday, October 15.

Investors sentiment increased to 1.64 in Q4 2018. Its up 0.28, from 1.36 in 2018Q3. It improved, as 13 investors sold Employers Holdings, Inc. shares while 43 reduced holdings. 33 funds opened positions while 59 raised stakes. 26.17 million shares or 2.13% more from 25.62 million shares in 2018Q3 were reported. Denali Advsrs Ltd invested 0% in Employers Holdings, Inc. (NYSE:EIG). The North Carolina-based State Bank Of America Corporation De has invested 0% in Employers Holdings, Inc. (NYSE:EIG). Tudor Inv Et Al accumulated 12,155 shares. New York State Teachers Retirement System has invested 0% in Employers Holdings, Inc. (NYSE:EIG). Martingale Asset Management Lp has 0.08% invested in Employers Holdings, Inc. (NYSE:EIG) for 138,860 shares. Envestnet Asset holds 0% or 7,632 shares. Citadel Advsrs Lc holds 44,829 shares. Hotchkis And Wiley Capital Llc reported 50,239 shares. Teachers Retirement System Of The State Of Kentucky reported 10,093 shares. Dimensional Fund Lp holds 2.72M shares or 0.05% of its portfolio. Opus Cap Gp Lc has 0.22% invested in Employers Holdings, Inc. (NYSE:EIG). Moody Bancorporation Division reported 0% stake. Bowling Portfolio Mgmt Lc owns 26,038 shares or 0.19% of their US portfolio. Renaissance Tech Ltd Liability Company invested in 301,900 shares or 0.01% of the stock. State Street Corporation holds 0% or 916,320 shares in its portfolio.

Employers Holdings, Inc. (NYSE:EIG) Institutional Positions Chart